17α-Hydroxylase/17,20-lyase is a target in the treatment of hormone-dependent prostate cancer. Here we report the results of a study into a range of alkanesulfonate derivatives of 4-hydroxybenzylimidazole which show the compounds to be good inhibitors with 5 [IC50=1.11μM (17α-OHase) and IC50=1.28μM (lyase)] being the most potent but weaker than ketoconazole.
|Number of pages||10|
|Journal||Letters in Drug Design & Discovery|
|Publication status||Published - 1 Oct 2014|
- Inhibitors Lyase